TY  - GEN
AU  - Paz-Ares,L
AU  - del Muro,J G
AU  - Grande,E
AU  - Díaz,S
TI  - A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System
SN  - 1365-2710
PY  - 2010///1227
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Carcinoma, Renal Cell
KW  - drug therapy
KW  - Cost-Benefit Analysis
KW  - Cytokines
KW  - therapeutic use
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Drug Costs
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Health Care Costs
KW  - Humans
KW  - Immunotherapy
KW  - Indoles
KW  - Kidney Neoplasms
KW  - Male
KW  - Markov Chains
KW  - Middle Aged
KW  - Models, Economic
KW  - Palliative Care
KW  - economics
KW  - Protein Kinase Inhibitors
KW  - Pyrroles
KW  - Quality-Adjusted Life Years
KW  - Spain
KW  - Sunitinib
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/j.1365-2710.2009.01135.x
ER  -